Clearside biomedical announces additional data from the cls-ax odyssey phase 2b trial presented at the angiogenesis, exudation, and degeneration 2025 meeting

- bcva and cst data from sub-group analyses provide key insights for planned cls-ax phase 3 trial design - - bcva and cst data from sub-group analyses provide key insights for planned cls-ax phase 3 trial design -

CLS Ratings Summary

CLS Quant Ranking